These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34602032)

  • 1. Metabolism is not a Major Contributor to the Toxicity of Piperaquine, a Long-acting Antimalarial Agent in Artemisinin-based Combination Therapy.
    Zhang L; Liu Z; Zhang Y; Xie Y; Xing J
    Curr Drug Metab; 2021; 22(10):824-834. PubMed ID: 34602032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers.
    Liu H; Zhou H; Cai T; Yang A; Zang M; Xing J
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine.
    Zang M; Zhu F; Zhao L; Yang A; Li X; Liu H; Xing J
    Malar J; 2014 Dec; 13():478. PubMed ID: 25476790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicology and pharmacokinetics of piperaquine in mice.
    Batty KT; Moore BR; Stirling V; Ilett KF; Page-Sharp M; Shilkin KB; Mueller I; Karunajeewa HA; Davis TM
    Toxicology; 2008 Jul; 249(1):55-61. PubMed ID: 18502018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Retroversion of Piperaquine (PQ) via Hepatic Cytochrome P450-Mediated
    Xie Y; Zhang Y; Liu H; Xing J
    Drug Metab Dispos; 2021 May; 49(5):379-388. PubMed ID: 33674271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination.
    Zang M; Zhu F; Li X; Yang A; Xing J
    Malar J; 2014 Jun; 13():214. PubMed ID: 24889062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No Effect of PXR (8055C>T) Polymorphism on the Pharmacokinetic Profiles of Piperaquine in Healthy Chinese Subjects.
    Liu H; Xie Y; Cai T; Xing J
    Curr Drug Metab; 2022; 23(2):164-170. PubMed ID: 35168517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
    Moore BR; Batty KT; Andrzejewski C; Jago JD; Page-Sharp M; Ilett KF
    Antimicrob Agents Chemother; 2008 Jan; 52(1):306-11. PubMed ID: 17984231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of reproductive toxicity of piperaquine in mice.
    Batty KT; Moore BR; Stirling V; Ilett KF; Page-Sharp M; Shilkin KB; Mueller I; Rogerson SJ; Karunajeewa HA; Davis TM
    Reprod Toxicol; 2010 Apr; 29(2):206-13. PubMed ID: 19892009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.
    Moore BR; Benjamin JM; Salman S; Griffin S; Ginny E; Page-Sharp M; Robinson LJ; Siba P; Batty KT; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5784-94. PubMed ID: 25049242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Retroconversion Metabolism of
    Zhou H; Zhang L; Ji J; Xie Y; Xing J
    Curr Drug Metab; 2023; 24(2):131-138. PubMed ID: 36941813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
    Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
    Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of malaria-induced alteration of metabolism on piperaquine disposition in Plasmodium yoelii infected mice and predicted in malaria patients.
    Xie Y; Zhang Y; Lin F; Chen X; Xing J
    Int J Antimicrob Agents; 2024 Jul; 64(1):107209. PubMed ID: 38761871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproductive and endocrine effects of artemisinin, piperaquine, and artemisinin-piperaquine combination in rats.
    Li X; Yuan Y; Chen Y; Ru L; Yuan Z; Xu Z; Xu Q; Song J; Li G; Deng C
    BMC Complement Med Ther; 2022 Oct; 22(1):268. PubMed ID: 36229813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.
    Salman S; Page-Sharp M; Batty KT; Kose K; Griffin S; Siba PM; Ilett KF; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3288-97. PubMed ID: 22470119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
    Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the active components in Tripterygium wilfordii leading to its acute hepatotoxicty and nephrotoxicity.
    Li XX; Du FY; Liu HX; Ji JB; Xing J
    J Ethnopharmacol; 2015 Mar; 162():238-43. PubMed ID: 25582490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of human urinary metabolites of the antimalarial piperaquine.
    Tarning J; Bergqvist Y; Day NP; Bergquist J; Arvidsson B; White NJ; Ashton M; Lindegårdh N
    Drug Metab Dispos; 2006 Dec; 34(12):2011-9. PubMed ID: 16956956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects.
    Röshammar D; Hai TN; Friberg Hietala S; Van Huong N; Ashton M
    Eur J Clin Pharmacol; 2006 May; 62(5):335-41. PubMed ID: 16570188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of the antimalarial piperaquine in plasma.
    Tarning J; Lindegardh N
    Trans R Soc Trop Med Hyg; 2008 May; 102(5):409-11. PubMed ID: 18378269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.